Skip to main content

Table 1 Characteristics of patients

From: Sirt1 expression is associated with CD31 expression in blood cells from patients with chronic obstructive pulmonary disease

Characteristics

Smoking control

Mild COPD

Moderate COPD

Severe COPD

GOLD

-

Stage I

Stage II

Stage III, IV

Number of patients

106

69

103

80

Age (years)

70.5 ± 9.4

72.2 ± 9.3

72.5 ± 8.8

73.9 ± 8.7

Gender (Male/Female)

(102/4)

(65/4)

(98/5)

(76/4)

FVC predict (%)

97.2 ± 14.2

114.1 ± 14.9*

97.3 ± 16.1

75.7 ± 18.1*

FEV1/FVC (%)

77.3 ± 6.1

64.5 ± 5.1*

52.8 ± 9.1*

39.3 ± 10.4*

FEV1% predict

96.1 ± 13.5

96.3 ± 13.3

64.5 ± 8.8*

37.5 ± 8.1*

LAA (%)

5.5 ± 6.1

10.7 ± 10.0

14.6 ± 10.7*

22.7 ± 14.6*

Smoking (Pack years)

61.4 ± 38.5

58.1 ± 33.7

60.5 ± 30.7

63.2 ± 29.2

Current smoker (no.)

31

22

29

19

Medication (no.)

 LABA

-

17

49

50

 LAMA

-

17

46

55

 ICS

-

11

36

38

CRP (mg/dl)

0.24 ± 0.34

0.31 ± 0.48

0.39 ± 0.77

0.46 ± 0.92

  1. COPD Chronic obstructive pulmonary disease, GOLD Global Initiative for Obstructive Lung Disease, FEV1 % predict Forced Expiratory Volume in 1 s % predicted, LAA Low attenuation area; change in FEV1 as a percent of baseline FEV1, LABA Long acting beta 2 agonist, LAMA Long acting muscarinic antagonist, ICS Inhaled corticosteroid
  2. Values are expressed as means ± SD. * p < 0.05 vs smoking control